Netherlands· NL-97f62836f330

Carblit 300 mg tabletten

A lithium product containing lithiumcarbonaat, registered in Netherlands by XGX Pharma ApS. The same ATC class is registered in 15 of our 19 countries.

ATC N05AN01

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about lithiumcarbonaatAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Lithium is registered in 15 of 19 countries.

Countries holding a registration under ATC N05AN01 (lithium), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
8 of them publish a price we can compare per daily dose

Search lithium products by name

Lithium · ATC N05AN01

15 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Germany
Icelandprice
Ireland
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: LITHIUMCARBONAAT
Manufacturer: XGX Pharma ApS
Country: Netherlands (NL)
ATC code: N05AN01
ATC class: Lithium
Defined daily dose: 24 mmol, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
137055

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

428 interactions on record for lithium.

Graded by severity as the source publishes them — 73 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check lithium against other medicines How interaction checks work

Lithium · interactions on record

428 records

73 severe
250 moderate
15 minor

Most severe, free to view

PapaverineA03AD01severe
CisaprideA03FA02severe
OndansetronA04AA01severe
GranisetronA04AA02severe

90 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lithium in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lithium products

Authorised across Europe · EMA

The same active substance is authorised in 24 EEA countries. Names it is sold under:

Austria · Lithiumchlorid Lidco, Neurolepsin
Belgium · Camcolit
Bulgaria · Lithibalance
Cyprus · Plenur
Czechia · Lithium Carbonicum Slovakofarma, Lithium Chlorid Lco
Germany · Hypnorex Retard, Quilonum Retard
Denmark · Carblit, Litarex
Spain · Cloruro De Litio Lidco Netherlands, Plenur
Finland · Lito
France · Lithioderm, Lithium Granions
United Kingdom (Northern Ireland) · Camcolit, Li-Liquid
Greece · Milithin
Croatia · Litijev Karbonat Jgl, Litijev Klorid Lidco
Hungary · Liticarb
Ireland · Camcolit, Lithium Chloride Lidco Netherlands
Iceland · Litarex
Italy · Carbolithium, Litio Carbonato L.F.M.
Luxembourg · Camcolit, Oligosol
Norway · Carblit, Lithium Chloride Lidco
Poland · Lithium Carbonicum Gsk
Portugal · Plenur, Priadel
Sweden · Carblit, Lithionit
Slovenia · Litijev Karbonat Lekarna Ljubljana
Slovakia · Lithium Carbonicum Slovakofarma

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/aea0fe52-330c-4ef1-82a3-766c394fc48b
GET /v1/drugs/aea0fe52-330c-4ef1-82a3-766c394fc48b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h137055_smpc.pdf",
  "strength": null,
  "atc_label": "Lithium",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg137055",
  "excipients": [
    "LACTOSE 1-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MAÏSZETMEEL",
    "NATRIUMZETMEELGLYCOLAAT (TYPE A)",
    "POVIDON K 25 (E 1201)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)"
  ],
  "substances": [
    "LITHIUMCARBONAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h137055.pdf",
  "authorised_at": "2026/07/14",
  "procedure_number": "DK/H/3494/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "137055",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about lithium.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console